As a patient, what should I know about the IMPACT-TD Registry?

What is the Teva IMPACT-TD Registry?

  • TD is a disorder in which the person is not in control of some of their body’s movements. The severity of TD is usually measured using a scale that rates how noticeable or pronounced these movements are. It is important to remember that TD also affects a person’s ability to go about their daily activities, and can often reduce quality of life1–3
  • The Registry is a study to collect information from people with TD to see how the condition develops over time and its impact on the person
  • As part of your usual care, you will complete questionnaires and visit your physician over 3 years to collect this information
  • This will help us to understand the effect TD has on a person’s life in a number of different areas, or ‘domains’

 

Why should I consider participating?

  • Your participation will help generate new information to shed light on how TD progresses over time and the extent to which it impacts a person's quality of life
  • Understanding and effectively assessing the many ways in which TD can impact peoples’ lives means that doctors can properly diagnose and develop care strategies for people with TD

 

What should I expect?

  • If your healthcare provider determines you are eligible and you agree to take part in the Registry study, you will be asked to visit your clinic to undertake an initial (‘baseline’) assessment which involves completing questionnaires about your TD movements and their impact on your daily life
  • After this, your TD movements will be evaluated by your healthcare provider and the impact of the movements on your daily life will be evaluated via questionnaires along with your routine appointments with your healthcare provider, over the course of 3 years

  1. Caroff SN, et al. J Clin Psychopharmacol 2020;40:259–68.
  2. Ascher-Svanum H, et al. J Clin Psychiatry 2008;69:1580–8.
  3. Ayyagari R, et al. Presented at Psych Congress 2019; October 3–6, 2019, San Diego, CA USA; Poster 116.